Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform
June 22, 2020
Invitae has entered into a definitive agreement to acquire ArcherDX in a cash-and-stock transaction valued at approximately $1.4 billion, combining Invitae's diagnostic and hereditary testing capabilities with ArcherDX's somatic genomics, liquid biopsy and bioinformatics platform. The deal is intended to integrate germline and somatic testing, expand precision oncology offerings, and accelerate adoption of comprehensive cancer genetics across clinical and biopharma customers worldwide.
- Buyers
- Invitae
- Targets
- ArcherDX
- Industry
- Healthcare Services
- Location
- Colorado, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Invitae Acquires YouScript and Genelex
March 10, 2020
Healthcare Services
Invitae Corporation has agreed to acquire YouScript, a clinical decision support and analytics platform, for approximately $79.3 million (cash and stock) and Genelex, a pharmacogenetic testing laboratory, for approximately $20.7 million in Invitae common stock plus potential milestone shares. The acquisitions integrate Genelex's pharmacogenetic testing and YouScript's real-time prescribing decision support into Invitae's genetics offerings to accelerate use of pharmacogenetics at the point of care.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
-
Exact Sciences Acquires Paradigm Diagnostics and Viomics
March 3, 2020
Healthcare Services
Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.
-
Veritas Genetics Acquires Curoverse
August 3, 2017
Biotechnology
Veritas Genetics has acquired Boston-based Curoverse, the creator of the Arvados open-source genomic data platform, for an undisclosed amount. The acquisition brings Curoverse’s bioinformatics, data-management and AI/ML capabilities in-house to expand Veritas’s capacity for large-scale genome interpretation and deploy machine learning across millions of genomes.
-
Tesis Biosciences Acquires Genome Explorations
February 16, 2022
Biotechnology
Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.
-
Castle Biosciences Acquires AltheaDx
April 26, 2022
Healthcare Services
Castle Biosciences (Nasdaq: CSTL) completed its acquisition of AltheaDx, a commercial-stage pharmacogenomics (PGx) molecular diagnostics company focused on mental health. Under the definitive agreement, AltheaDx became a wholly owned subsidiary of Castle, and Castle paid $65.0 million at closing plus up to $75.0 million in potential milestone-based consideration tied to performance and expanded Medicare coverage for IDgenetix.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.